Voluntary disclosure and its impact on share prices: Evidence from the UK biotechnology sector

Elisabeth Dedman, Lin, Stephen W.-J, Arun J. Prakash () and Chang, Chun-Hao

Journal of Accounting and Public Policy, 2008, vol. 27, issue 3, pages 195-216

Abstract: In the UK, SSAP 13 requires that firms immediately expense most of their R&D expenditures. The reported earnings of high-R&D expenditure firms are therefore likely to convey less value-relevant information to investors than those of less research-intensive firms. Using a sample of firms from the high-R&D UK biotechnology/pharmaceutical sector, we find that earnings announcements have a much lower price impact than drug development announcements. We also find that there are significantly more [`]good news' voluntary announcements than [`]bad news' announcements. Furthermore, our findings indicate that these firms are more likely to announce late than early stage developments, and that the pattern of disclosures, and the market's reaction to them, varies between larger, dominant firms and their smaller counterparts.

Date: 2008

Downloads: (external link)
http://www.sciencedirect.com/science/article/B6VBG ... 286e0a3cdc1186698ffe
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:eee:jappol:v:27:y:2008:i:3:p:195-216

Access Statistics for this article

Journal of Accounting and Public Policy is edited by L. A. Gordon

More articles in Journal of Accounting and Public Policy from Elsevier
Series data maintained by Heidi Boesdal ().